Resumen
Background: Atrial fibrillation (AF) is a substantial burden on health care. Combined specialist and nurse-based AF clinics are associated with improved outcomes. However, Canadian data on the cost-effectiveness of this integrated management approach to AF care are lacking. Methods: We evaluated health care costs and outcomes of 413 patients with newly-diagnosed AF in 3 emergency departments in Nova Scotia between January 1, 2011 and January 31, 2014. Using a before-after study design, patients were divided into usual care (228 patients) and intervention (185 patients) groups. The intervention was a nurse-run, physician-supervised AF clinic. Costs and quality-adjusted life years (QALYs) were compared between usual care and intervention. Costs were those incurred because of the clinical outcome, bleeding events, medications, and cardiovascular-related procedures. Probabilistic analysis was conducted to assess uncertainty. Results: The AF clinic was associated with an average cost reduction of CAD$210.83 and an average improvement in QALY of 0.0007 per patient. The AF clinic was dominant over usual care despite higher operational and medication costs over 1 year. It provided greater cost-saving in approximately 66% of probabilistic analysis simulations and generated more QALYs in approximately 92% of simulations. An incremental cost-effectiveness ratio < $50,000 was found in 68% of simulations. Conclusions: The present study provides guidance regarding the cost-effectiveness of an integrated management approach compared with usual specialty care of AF in a Canadian setting. We recommend further study be undertaken that prospectively plans for economic evaluation before definitive assessments of cost-effectiveness can be made.
Idioma original | English |
---|---|
Páginas (desde-hasta) | 1142-1148 |
Número de páginas | 7 |
Publicación | Canadian Journal of Cardiology |
Volumen | 35 |
N.º | 9 |
DOI | |
Estado | Published - sep. 2019 |
Publicado de forma externa | Sí |
Nota bibliográfica
Funding Information:Dr Parkash has received research grant funding from Pfizer Canada , Bayer Canada and Boehringer-Ingelheim . The other authors have no conflicts of interest to disclose.
Funding Information:
Funding for this study was provided by Pfizer Canada , Bayer Canada , Boehringer-Ingelheim , Nova Scotia Health Authority Research Fund and the Cardiac Arrhythmia Network of Canada as part of the Networks of Centres of Excellence. The authors acknowledge the support provided by the Research in Medicine program at Dalhousie University’s Faculty of Medicine.
Publisher Copyright:
© 2019 Canadian Cardiovascular Society
ASJC Scopus Subject Areas
- Cardiology and Cardiovascular Medicine